Skip to content
10-Q

Quarterly Report

enGene Therapeutics Inc. ENGN ENGNW

0001193125-26-270386

← back to feed
Filed
Jun 15, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2026 · Jun 9, 2026 66.99M sh
Shares Diluted Q2 2026 · Apr 30, 2026 69.72M sh
Shares Diluted Q2 2026 · Apr 30, 2026 68.47M sh
Shares Diluted Q2 2026 · Apr 30, 2025 51.02M sh
Shares Diluted Q2 2026 · Apr 30, 2025 51M sh
Capex Q2 2026 · Apr 30, 2026 $251K
Capex Q2 2026 · Apr 30, 2025 $344K
Operating Cash Flow Q2 2026 · Apr 30, 2026 −$59.4M
Operating Cash Flow Q2 2026 · Apr 30, 2025 −$48.64M
Cash And Equivalents Q2 2026 · Apr 30, 2026 $29.83M
Cash And Equivalents Q2 2026 · Oct 31, 2025 $50.15M
Stockholders Equity Q2 2026 · Apr 30, 2026 $255.17M
Stockholders Equity Q2 2026 · Jan 31, 2026 $281.55M
Stockholders Equity Q2 2026 · Oct 31, 2025 $167.71M
Stockholders Equity Q2 2026 · Apr 30, 2025 $227.29M
Stockholders Equity Q2 2026 · Jan 31, 2025 $249.95M
Stockholders Equity Q2 2026 · Oct 31, 2024 $272.61M
Current Liabilities Q2 2026 · Apr 30, 2026 $21.49M
Current Liabilities Q2 2026 · Oct 31, 2025 $31.98M
Total Liabilities Q2 2026 · Apr 30, 2026 $52.36M
Total Liabilities Q2 2026 · Oct 31, 2025 $53.76M
Current Assets Q2 2026 · Apr 30, 2026 $270M
Current Assets Q2 2026 · Oct 31, 2025 $201.39M
Total Assets Q2 2026 · Apr 30, 2026 $307.52M
Total Assets Q2 2026 · Oct 31, 2025 $221.47M
Eps Diluted Q2 2026 · Apr 30, 2026 −$0.43
Eps Diluted Q2 2026 · Apr 30, 2026 −$0.88
Eps Diluted restated Q2 2026 · Apr 30, 2025 −$0.51
Eps Diluted restated Q2 2026 · Apr 30, 2025 −$0.99
Eps Basic Q2 2026 · Apr 30, 2026 −$0.43
Eps Basic Q2 2026 · Apr 30, 2026 −$0.88
Eps Basic restated Q2 2026 · Apr 30, 2025 −$0.51
Eps Basic restated Q2 2026 · Apr 30, 2025 −$0.99
Sga Expense Q2 2026 · Apr 30, 2026 $9.77M
Sga Expense Q2 2026 · Apr 30, 2026 $18.7M
Sga Expense Q2 2026 · Apr 30, 2025 $6.92M
Sga Expense Q2 2026 · Apr 30, 2025 $13.55M
Rd Expense Q2 2026 · Apr 30, 2026 $22.2M
Rd Expense Q2 2026 · Apr 30, 2026 $44.45M
Rd Expense Q2 2026 · Apr 30, 2025 $20.21M
Rd Expense Q2 2026 · Apr 30, 2025 $40.18M
Net Income Q2 2026 · Apr 30, 2026 −$30.23M
Net Income Q2 2026 · Apr 30, 2026 −$59.98M
Net Income Q2 2026 · Jan 31, 2026 −$29.75M
Net Income Q2 2026 · Apr 30, 2025 −$25.82M
Net Income Q2 2026 · Apr 30, 2025 −$50.43M
Net Income Q2 2026 · Jan 31, 2025 −$24.62M
Operating Income Q2 2026 · Apr 30, 2026 −$31.97M
Operating Income Q2 2026 · Apr 30, 2026 −$63.15M
Operating Income Q2 2026 · Apr 30, 2025 −$27.12M
Operating Income Q2 2026 · Apr 30, 2025 −$53.74M